Page last updated: 2024-12-06

cefmetazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cefmetazole is a broad-spectrum cephalosporin antibiotic with a unique chemical structure that includes a methoxymethyl group at the 7-position. This modification contributes to its enhanced stability against enzymatic degradation, particularly by beta-lactamases produced by resistant bacteria. It exhibits activity against a wide range of Gram-positive and Gram-negative bacteria, including Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, and Klebsiella pneumoniae. Cefmetazole's mechanism of action involves inhibiting the synthesis of peptidoglycans, essential components of bacterial cell walls, ultimately leading to bacterial cell death. Its importance lies in its effectiveness against both penicillin-sensitive and penicillin-resistant strains of bacteria, making it a valuable therapeutic option for treating a variety of infections. Due to its unique structure and pharmacological properties, cefmetazole continues to be studied for its potential applications in treating infections resistant to other antibiotics. Research efforts focus on investigating its efficacy in various clinical settings, exploring its pharmacokinetic and pharmacodynamic properties, and evaluating its safety and tolerability in different patient populations.'

Cefmetazole: A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

cefmetazole : A second-generation cephalosporin antibiotic having N(1)-methyltetrazol-5-ylthiomethyl, {[(cyanomethyl)sulfanyl]acetyl}amino and methoxy side-groups at positions 3, 7beta and 7alpha respectively of the parent cephem bicyclic structure. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

2-phenoxy-1-phenylethanone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID42008
CHEMBL ID1201195
CHEBI ID3489
SCHEMBL ID147832
MeSH IDM0023575
PubMed CID222171
CHEMBL ID239513
CHEBI ID52401
SCHEMBL ID1068092
MeSH IDM0023575

Synonyms (100)

Synonym
AC-13154
(6r,7s)-7-(2-((cyanomethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thiomethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, sodium salt
(6r,7s)-7-[[2-(cyanomethylsulfanyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7s)-7-({[(cyanomethyl)thio]acetyl}amino)-7-(methyloxy)-3-{[(1-methyl-1h-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
LOPAC0_000266
PRESTWICK3_000700
BSPBIO_000859
PRESTWICK2_000700
56796-20-4
cefmetazole
C08103
(6r,7s)-7-({[(cyanomethyl)sulfanyl]acetyl}amino)-7-methoxy-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
DB00274
D00910
cefmetazole (usp/inn)
cefmetazolum [inn-latin]
cs 1170
(6r,7s)-7-(2-((cyanomethyl)thio)acetamido)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
brn 0634647
5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((((cyanomethyl)thio)acetyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, (6r-cis)-
skf 83088
u 72791
einecs 260-384-2
cefmetazolo [inn-spanish]
PRESTWICK1_000700
SPBIO_002780
PRESTWICK0_000700
BPBIO1_000945
cefmetazolo
cefmetazolum
7beta-{[(cyanomethyl)sulfanyl]acetamido}-7alpha-methoxy-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}ceph-3-em-4-carboxylic acid
CHEBI:3489 ,
(6r,7s)-7-[2-(cyanomethylsulfanyl)ethanoylamino]-7-methoxy-3-[(1-methyl-1,2,3,4-tetrazol-5-yl)sulfanylmethyl]-8-oxidanylidene-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
A831178
(6r,7s)-7-[[2-(cyanomethylthio)-1-oxoethyl]amino]-7-methoxy-3-[[(1-methyl-5-tetrazolyl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CHEMBL1201195
u-72791
bdbm50350471
3j962ujt8h ,
unii-3j962ujt8h
cefmetazole [usan:usp:inn]
EPITOPE ID:116204
AKOS015896219
SCHEMBL147832
(6r,7s)-7-[2-[(cyanomethyl)thio]acetamido]-7-methoxy-3-[[(1-methyl-1h-tetrazol-5-yl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
cefmetazole [vandf]
cefmetazole [usp monograph]
cefmetazole sodium [jan]
cefmetazole [usp-rs]
cefmetazole [who-dd]
cefmetazole [mi]
cefmetazole [usan]
cefmetazole [inn]
cefmetazole [usp impurity]
cefmetazole [mart.]
J-700159
cefmetazolesodium
DTXSID7022756
(6r,7s)-7-{2-[(cyanomethyl)sulfanyl]acetamido}-7-methoxy-3-{[(1-methyl-1h-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7s)-7-(2-(cyanomethylthio)acetamido)-7-methoxy-3-((1-methyl-1h-tetrazol-5-ylthio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6r,7s)-7-({[(cyanomethyl)sulfanyl]acetyl}amino)-7-methoxy-3-{[(1-methyl-1h-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia
-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
mfcd00865068
BCP11998
Q5057238
2,6-difluoro-4-methoxyacetophenone
SDCCGSBI-0050254.P002
56796-20-4 (free)
5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid,7-[[[(cyanomethyl)thio]acetyl]amino]-7-methoxy-3-[[(1-methyl-1h-tetrazol-5-yl)thio]methyl]-8-oxo-, (6r,7s)-
BS-42476
EN300-19766367
gtpl12215
HY-B1595
CS-0013513
AKOS008908306
721-04-0
nsc7586
nsc-7586
mls002638022 ,
CHEBI:52401 ,
2-phenoxy-1-phenylethanone
2-phenoxy-1-phenylethan-1-one
2-phenoxyacetophenone
alpha-phenoxyacetophenone
smr001547525
CHEMBL239513
HMS3085O09
2-phenoxy-1-phenyl-ethanone
KRSXGTAVHIDVPM-UHFFFAOYSA-N
2-phenoxy-1-phenyl ethanone
SCHEMBL1068092
mfcd00156689
a-phenoxyacetophenone
P2121
AS-57740
DTXSID80992818
Q27123418
A856467
CS-0156550
SY056476

Research Excerpts

Overview

Cefmetazole (CMZ) is an antibiotic agent belonging to the cephamycin group, which is resistant to beta-lactamase and has a broad antibacterial spectrum covering from Gram-negative to -positive organisms. It is a valuable therapeutic alternative to carbapenems for treating pyelonephritis caused by Enterobacteriaceae.

ExcerptReferenceRelevance
"Cefmetazole is a valuable therapeutic alternative to carbapenems for treating pyelonephritis caused by ESBL-producing Enterobacteriaceae."( Cefmetazole for extended-spectrum β-lactamase-producing Enterobacteriaceae in pediatric pyelonephritis.
Aizawa, Y; Araki, K; Fukuoka, K; Higuchi, H; Horikoshi, Y, 2019
)
2.68
"Cefmetazole was suggested to be a useful antibiotic for the treatment of urinary tract infections."( [Clinical experience with cefmetazole in the urological field].
Aga, Y; Ogura, K; Yano, M, 1983
)
1.29
"Cefmetazole is a safe and effective antibiotics in treating severe infections in newborn and immature infants."( [Clinical usefulness of cefmetazole in newborn and immature infants (author's transl)].
, 1981
)
1.29
"Cefmetazole (CMZ) is an antibiotic agent belonging to the cephamycin group, which is resistant to beta-lactamase and has a broad antibacterial spectrum covering from Gram-negative to -positive organisms. "( [Laboratory and clinical studies of cefmetazole in serious infection by Staphylococcus (author's transl)].
Baba, Y; Fujimoto, T; Ishimoto, K; Komatsu, R; Kusayanagi, T; Motohiro, T; Nishiyama, T; Onoda, Y; Sakata, Y; Tanaka, C; Tominaga, K; Toubo, Y; Tsuboi, M; Yamamoto, M; Yamashita, F, 1982
)
1.98
"Cefmetazole sodium is a semisynthetic cephamycin antibiotic. "( Cefmetazole sodium: pharmacology, pharmacokinetics, and clinical trials.
Schentag, JJ, 1991
)
3.17
"Cefmetazole is a new semisynthetic derivative with a broad antibacterial spectrum as shown by data from 34 research institutes in Japan. "( [Clinical experience with a new antibiotic: cefmetazole].
Caviglia, MG; Civelli, D; De Lorenzi, E; Del Nero, E; Gianioro, F, 1990
)
1.98
"Cefmetazole (CM) is a new broad spectrum parenteral cephamycin antibiotic."( Controlled comparison of cefmetazole with cefoxitin for prophylaxis in elective cholecystectomy.
Appleman, MD; Berne, TV; Chenella, FC; Gill, MA; Heseltine, PN; Yellin, AE, 1990
)
1.3
"Cefmetazole is a cephamycin antibiotic which is resistant to hydrolysis by various beta-lactamases. "( Pharmacokinetics of intravenous cefmetazole with emphasis on comparison between predicted theoretical levels in tissue and actual skin window fluid levels.
File, TM; Hoffman, HE; Salstrom, SJ; Signs, SA; Tan, JS, 1989
)
2

Effects

Cefmetazole (CMZ) has received attention as a pharmaceutical intervention for extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) infections. It has a high safety rating when used in perinatal stage chemotherapy and thus it is a very useful antibiotic.

ExcerptReferenceRelevance
"Cefmetazole has a high safety rating when used in perinatal stage chemotherapy and thus it is a very useful antibiotic. "( [A study of safety of cefmetazole (CS-1170) in pregnant women during the perinatal stage (author's transl)].
, 1981
)
2.02
"Cefmetazole (CMZ) has received attention as a pharmaceutical intervention for extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) infections. "( Cefmetazole as an Alternative to Carbapenems Against Extended-Spectrum Beta-Lactamase-Producing Escherichia coli Infections Based on In Vitro and In Vivo Pharmacokinetics/Pharmacodynamics Experiments.
Enoki, Y; Hayashi, M; Igarashi, Y; Kojima, N; Liu, X; Matsumoto, K; Mizukami, Y; Morita, T; Nakamura, T; Taguchi, K; Takemura, W; Tashiro, S; Yokoyama, Y, 2021
)
3.51
"Cefmetazole (CMZ) has gained interest as a carbapenem-sparing alternative to the epidemic of extended-spectrum β-lactamase (ESBL)-producing Enterobacterales (ESBL-E). "( Pharmacokinetics of cefmetazole in plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue of patients scheduled for lower gastrointestinal surgery: Dosing considerations based on site-specific pharmacodynamic target attainment.
Hirano, T; Ikawa, K; Kaiki, Y; Kitagawa, H; Morikawa, N; Ohge, H; Shigemoto, N; Takahashi, S; Uegami, S; Watadani, Y; Yoshimura, K, 2023
)
2.68
"Cefmetazole has a high safety rating when used in perinatal stage chemotherapy and thus it is a very useful antibiotic. "( [A study of safety of cefmetazole (CS-1170) in pregnant women during the perinatal stage (author's transl)].
, 1981
)
2.02
"Cefmetazole has demonstrated excellent stability to aerobic and anaerobic organism-produced beta-lactamases."( Cefmetazole (CS-1170), a "new" cephamycin with a decade of clinical experience.
Jones, RN,
)
2.3

Treatment

Cefmetazole-treated bacterial attachment (44 +/- 28; mean +/- S.D.) decreased significantly (p less than 0.05) compared to the control (84 +/- 27). Treatment with cefmetzole and cefotaxime led him to a complete recovery without neurologic deficit.

ExcerptReferenceRelevance
"Cefmetazole-treated bacterial attachment (44 +/- 28; mean +/- S.D.) decreased significantly (p less than 0.05) compared to the control (84 +/- 27)."( Effect of ampicillin, cefmetazole and minocycline on the adherence of Branhamella catarrhalis to pharyngeal epithelial cells.
Ahmed, K; Matsumoto, K; Nagatake, T; Rikitomi, N; Watanabe, K; Yoshida, T, 1990
)
1.32
"Treatment with cefmetazole and cefotaxime led him to a complete recovery without neurologic deficit."( [A case of neonatal meningitis due to Flavobacterium meningosepticum successfully treated with cefmetazole and cefotaxime].
Arai, S; Fukuda, C; Kiyohara, K; Shimohira, M; Takeda, A; Toyoura, T, 1988
)
0.83

Toxicity

The safe dose of cefmetazole (CMZ) to the mother in the perinatal period is 1 approximately equal to 2 g/day. A total of 51 adverse events was noted in 68 patients: 36 in 26 patients (55%) in the cef metazole group and 15 in 12 patients (57%) inthe cefoxitin group.

ExcerptReferenceRelevance
" Cefmetazole, at a dose of 1 g intramuscularly preoperatively, is a safe and effective agent for prophylaxis during hysterectomy."( Cefmetazole and cefonicid. Comparative efficacy and safety in preventing postoperative infections after vaginal and abdominal hysterectomy.
Azen, CG; Cendejas, KA; Essin, DJ; Galvan, NI; March, CM; Neal, J; Ressler, RL; Roy, S; Solera, NC; Wilkins, J, 1990
)
2.63
" A total of 51 adverse events was noted in 68 patients: 36 in 26 patients (55%) in the cefmetazole group and 15 in 12 patients (57%) in the cefoxitin group."( Comparative evaluation of safety and efficacy of cefmetazole and cefoxitin in lower respiratory tract infections.
Chmel, H; Halkias, KD; Kenyon, VS; Toney, JF; Yangco, BG, 1989
)
0.75
" The principal adverse effect noted in the adult rats receiving the largest doses (2000 and 2500 mg/kg/day) of cefmetazole was slight elevation of serum alanine aminotransferase."( Preclinical safety studies of cefmetazole.
Manabe, J; Moe, JB; Piper, RC; Sotani, K; Tanase, H, 1989
)
0.78
"Nephrotoxicity of cefodizime sodium (THR-221), a new cephem antibiotic, was studied in rats by comparing its toxic effect with those of other cephem antibiotics including cephaloridine (CER), cefazolin (CEZ) and cefmetazol (CMZ)."( [Nephrotoxicity of cefodizime sodium in rats--single and 14-day repeated intravenous administration].
Hayashi, T; Irimura, K; Kuwata, M; Maruden, A; Morita, K, 1988
)
0.27
" The LD50 values determined in male and female mice were 26."( Improvement of bioavailability of poorly absorbed drugs. III. Oral acute toxicity and local irritation of medium chain glyceride.
Awazu, S; Fukami, M; Kimura, K; Maeda, E; Okada, R; Sasahara, K; Sekine, M, 1985
)
0.27
" The safe dose of cefmetazole (CMZ) to the mother in the perinatal period is 1 approximately equal to 2 g/day."( [A study of safety of cefmetazole (CS-1170) in pregnant women during the perinatal stage (author's transl)].
, 1981
)
0.91
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
"Cefmetazole is effective and safe in the treatment of aspiration pneumonia."( [The clinical efficacy and safety of intravenous cefmetazole in treatment of 1,522 patients with aspiration pneumonia].
Li, Q; Zhang, XY; Zhou, X, 2011
)
2.07
" The selectivity index (SI) of LS-2 (1) was 91 and the calculated LD50 was 1870 mg/kg, highlighting the very low toxicity in mice."( Structure activity relationship, acute toxicity and cytotoxicity of antimycobacterial neolignan analogues.
Alderete, JB; Barata, LE; da Silva Melo, P; de Souza, AO; Ferreira, I; Minarini, PR; Silva, CL, 2011
)
0.37

Pharmacokinetics

The pharmacokinetic parameters of cefmetazole were derived by analyzing elimination data, with a one-compartment open model. Pharmacokinetic analysis of results indicated that unbound cef Metazole levels in rats best fit a biexponential decay model.

ExcerptReferenceRelevance
" Comparisons of pharmacokinetic parameters between the young and elderly groups indicated that the systemic clearance was significantly lower in elderly than in young volunteers (92."( Pharmacokinetics and dose proportionality of cefmetazole in healthy young and elderly volunteers.
Borin, MT; Peters, GR; Smith, TC, 1990
)
0.54
"05) higher mean (+/- standard error of the mean) peak concentration in serum (290 +/- 11 versus 244 +/- 10 micrograms/ml), a longer terminal disposition half-life (1."( Pharmacokinetics of intravenously administered cefmetazole and cefoxitin and effects of probenecid on cefmetazole elimination.
Adams, WJ; Cathcart, KS; Griffith, DL; Ko, H; Peters, GR, 1989
)
0.53
" The drug was well tolerated, with no adverse medical events or laboratory changes observed during the study that could affect the pharmacokinetic interpretation of the data."( Pharmacokinetics of single-dose cefmetazole following intramuscular administration of cefmetazole sodium to healthy male volunteers.
Adams, WJ; Bothwell, WM; Closson, SK; Hosley, JD; Ko, H; Novak, E; Peters, GR, 1989
)
0.56
" The pharmacokinetic parameters of cefmetazole were derived by analyzing elimination data, with a one-compartment open model."( Pharmacokinetics of cefmetazole in normal subjects and in patients with impaired renal function.
Kuroda, K; Nakashita, E; Ohkawa, M; Orito, M; Sasahara, K; Sawaki, M; Shimamura, M; Sugata, T, 1980
)
0.86
" Pharmacokinetic analysis of results indicated that unbound cefmetazole levels in rats best fit a biexponential decay model."( Determination of unbound cefmetazole in rat blood by on-line microdialysis and microbore liquid chromatography: a pharmacokinetic study.
Chen, CF; Cheng, FC; Hung, LC; Tsai, TH; Tsai, TR, 1999
)
0.85
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" In this study, we investigated the pharmacokinetics (PK) of CMZ in plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue to assess the dosing regimen needed to achieve pharmacodynamic (PD) goals at the target site."( Pharmacokinetics of cefmetazole in plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue of patients scheduled for lower gastrointestinal surgery: Dosing considerations based on site-specific pharmacodynamic target attainment.
Hirano, T; Ikawa, K; Kaiki, Y; Kitagawa, H; Morikawa, N; Ohge, H; Shigemoto, N; Takahashi, S; Uegami, S; Watadani, Y; Yoshimura, K, 2023
)
1.23

Compound-Compound Interactions

The antibacterial activities of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant (MR) strains of Staphylococcus aureus were investigated. The in-vitro activity of imipenem combined with beta-lactam antibiotics was studied.

ExcerptReferenceRelevance
"The in-vitro activity of imipenem combined with beta-lactam antibiotics was studied for 25 strains of methicillin and imipenem-resistant Staphylococcus aureus (MRSA) in comparison with that of fosfomycin combined with cefmetazole."( In-vitro activity of imipenem combined with beta-lactam antibiotics for methicillin-resistant Staphylococcus aureus.
Asahi, Y; Inoue, M; Matsuda, K; Nakagawa, S; Sanada, M; Tanaka, N, 1991
)
0.47
"In vitro and in vivo antibacterial activities of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant (MR) strains of Staphylococcus aureus were investigated, and the mechanism of synergistic effect between cefmetazole and fosfomycin was also studied."( Antibacterial activity of cefmetazole alone and in combination with fosfomycin against methicillin- and cephem-resistant Staphylococcus aureus.
Magaribuchi, T; Ohya, S; Tajima, M; Utsui, Y; Yokota, T, 1986
)
0.83

Bioavailability

The bioavailability of cefmetazole, determined by area under the blood concentration curve method, increased 20 to 30% by the coadministration of calmodulin inhibitors.

ExcerptReferenceRelevance
"We examined the enhancing effect of sodium caprate (C10) on the jejunal absorption of a poorly absorbed drug, cefmetazole, in rats, in comparison with its colonic absorption (Pharm."( Differences in the enhancing effects of sodium caprate on colonic and jejunal drug absorption.
Awazu, S; Hayashi, M; Ogawa, T; Ouchi, H; Sawada, T; Tomita, M, 1992
)
0.5
" The bioavailability of cefmetazole, determined by area under the blood concentration curve method, increased 20 to 30% by the coadministration of calmodulin inhibitors."( Effects of phenothiazines and N-(6-aminohexyl)-5-chloro-1-naphthalenesulfonamide on rat colonic absorption of cefmetazole.
Furuya, A; Kamada, A; Nishihata, T; Suzuka, T, 1986
)
0.79
" Furthermore, the oral bioavailability of pharmaceutical formulations of CMZ was also investigated in dogs."( Improvement of bioavailability of poorly absorbed drugs. II. Effect of medium chain glyceride base on the intestinal absorption of cefmetazole sodium in rats and dogs.
Awazu, S; Nishimura, K; Okada, R; Sasahara, K; Sekine, M; Terashima, H, 1985
)
0.47
" The bioavailability of both antibiotics appeared to depend on the concentration of the adjuvant in the microenema, the dosage form used in these experiments."( Enhanced rectal absorption of cefmetazole and cefoxitin in the presence of epinephrine metabolites in rats and a high-performance liquid chromatographic assay for cephamycin antibiotics.
Higuchi, T; Nishihata, T; Rytting, JH; Takahagi, H; Tomida, H; Yamamoto, M, 1984
)
0.56
" Phenylalanine and phenylalanylglycine, both poorly absorbed across the rectal membrane when administered alone, did not enhance the rectal absorption of either antibiotic."( The effects of salicylate on the rectal absorption of phenylalanine and some peptides, and the effects of these peptides on the rectal absorption of cefoxitin and cefmetazole.
Higuchi, T; Lee, CS; Nishihata, T; Rytting, JH; Yamamoto, M, 1984
)
0.46
"The utilization of the membrane transport protein PEPT1 as a drug delivery system is a promising strategy to enhance the oral bioavailability of drugs."( Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
Biegel, A; Brandsch, M; Gebauer, S; Hartrodt, B; Neubert, K; Thondorf, I, 2005
)
0.33

Dosage Studied

Cefmetazole and cefotetan were as effective and less expensive than multiple doses of short-acting agents. An intermediate category was proposed for MICs greater than 2-4 micrograms/m (28-32 mm) pending more clinical experience with higher and/or prolonged dosing regimens. The most consistent effects of longterm multiple dosing with cefmetzole in dogs consisted of.

ExcerptRelevanceReference
" An intermediate category was proposed for MICs greater than 2-4 micrograms/m (28-32 mm) pending more clinical experience with higher and/or prolonged cefmetazole dosing regimens."( Cefmetazole and trospectomycin in vitro susceptibility testing interpretive criteria and quality control guidelines for Neisseria gonorrheae.
Erwin, ME; Gerlach, EH; Jones, RN; Koontz, FP; Murray, PR; Washington, JA,
)
1.77
" Agents with longer half lives allowing twice daily dosing (cefmetazole and cefotetan) were as effective and less expensive than multiple doses of short-acting agents."( Adjunctive antimicrobials in surgery of soft tissue infections: evaluation of cephalosporins and carbapenems.
Hopkins, JA; Lami, JL; Wilson, SE, 1991
)
0.52
" Serial plasma and urine samples were collected over a 24-h period following dosing and assayed for cefmetazole by a high-performance liquid chromatography method."( Pharmacokinetics and dose proportionality of cefmetazole in healthy young and elderly volunteers.
Borin, MT; Peters, GR; Smith, TC, 1990
)
0.76
" The most consistent effects of longterm multiple dosing with cefmetazole in dogs consisted of vomiting and retching during dosing and reversible haematological changes (mild regenerative anaemia, positive Coombs' test, clinically-silent thrombocytopenia) in a number of the dogs."( Preclinical safety studies of cefmetazole.
Manabe, J; Moe, JB; Piper, RC; Sotani, K; Tanase, H, 1989
)
0.81
"The minimum dosage of antibiotics which reduced mortality in rats intraperitoneally inoculated with an Escherichia coli isolate was determined."( In vivo significance of the inoculum effect of antibiotics on Escherichia coli.
Castilla, C; Fernández-Roblas, R; Ponte, C; Santamaría, M; Soriano, F, 1988
)
0.27
" Each drug was administered single and consecutive 14-day dosage with its alone or in combination with either furosemide or gentamicin."( [Nephrotoxicity of cefodizime sodium in rats--single and 14-day repeated intravenous administration].
Hayashi, T; Irimura, K; Kuwata, M; Maruden, A; Morita, K, 1988
)
0.27
" The promoting effect of MCG was found to be mainly due to glycerylmonocaprylate and dependent on the dosage of MCG."( Improvement of bioavailability of poorly absorbed drugs. II. Effect of medium chain glyceride base on the intestinal absorption of cefmetazole sodium in rats and dogs.
Awazu, S; Nishimura, K; Okada, R; Sasahara, K; Sekine, M; Terashima, H, 1985
)
0.47
" Based on the above clinical results, it can be concluded that, in the treatment of complicated urinary tract infections, we can expect CTT to provide the same therapeutic efficacy as CMZ when its dosage is the same or even half thereof."( [Double-blind comparison of cefotetan and cefmetazole in complex urinary tract infections].
Arakawa, S; Fujimura, N; Ishigami, J; Ishino, T; Ishito, N; Kamidono, S; Kurokawa, K; Nihira, H; Ohmori, H; Umezu, K, 1983
)
0.53
" The bioavailability of both antibiotics appeared to depend on the concentration of the adjuvant in the microenema, the dosage form used in these experiments."( Enhanced rectal absorption of cefmetazole and cefoxitin in the presence of epinephrine metabolites in rats and a high-performance liquid chromatographic assay for cephamycin antibiotics.
Higuchi, T; Nishihata, T; Rytting, JH; Takahagi, H; Tomida, H; Yamamoto, M, 1984
)
0.56
" Costs of the agents were calculated based on the dosage and administration schedules typically used in published clinical trials of cefmetazole and cefoxitin and on the typical dosing patterns of cefoxitin used at Presbyterian Hospital."( Projected cost savings associated with cefmetazole: a new cephamycin for the hospitalized patient.
Crane, VS, 1991
)
0.75
"Intraoperative repeated antimicrobial dosing is therefore recommended to prevent the surgical wound infection for prolonged colorectal surgery."( The significance of the intraoperative repeated dosing of antimicrobials for preventing surgical wound infection in colorectal surgery.
Fukushima, Y; Hiraoka, N; Morimoto, T; Morita, S; Nishisho, I; Nomura, T; Shibata, N, 2005
)
0.33
" Therefore, we aimed to evaluate the efficacy and appropriate dosing of cefmetazole (CMZ) in invasive urinary tract infection (iUTI) caused by ESBL-producing Escherichia coli (ESBLEC)."( Retrospective evaluation of appropriate dosing of cefmetazole for invasive urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli.
Akazawa, T; Doi, Y; Hamada, Y; Hayakawa, K; Matsumura, Y; Nagashima, M, 2021
)
1.11
" In this study, we investigated the pharmacokinetics (PK) of CMZ in plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue to assess the dosing regimen needed to achieve pharmacodynamic (PD) goals at the target site."( Pharmacokinetics of cefmetazole in plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue of patients scheduled for lower gastrointestinal surgery: Dosing considerations based on site-specific pharmacodynamic target attainment.
Hirano, T; Ikawa, K; Kaiki, Y; Kitagawa, H; Morikawa, N; Ohge, H; Shigemoto, N; Takahashi, S; Uegami, S; Watadani, Y; Yoshimura, K, 2023
)
1.23
"These findings clarify the PK of CMZ in abdominal tissues and could help decide optimal dosing regimens to treat intra-abdominal infection and prophylaxis of SSI."( Pharmacokinetics of cefmetazole in plasma, peritoneal fluid, peritoneum, and subcutaneous adipose tissue of patients scheduled for lower gastrointestinal surgery: Dosing considerations based on site-specific pharmacodynamic target attainment.
Hirano, T; Ikawa, K; Kaiki, Y; Kitagawa, H; Morikawa, N; Ohge, H; Shigemoto, N; Takahashi, S; Uegami, S; Watadani, Y; Yoshimura, K, 2023
)
1.23
" The purpose of this study was to investigate a novel treatment for TB meant to improve patient compliance by reducing drug dosage frequency."( Antimycobacterial activity of 2-phenoxy-1-phenylethanone, a synthetic analogue of neolignan, entrapped in polymeric microparticles.
Barata, LE; Bentley, MV; de Souza, AO; Minarini, PR; Silva, CL; Soares, EG, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
cephalosporinA class of beta-lactam antibiotics differing from the penicillins in having a 6-membered, rather than a 5-membered, side ring. Although cephalosporins are among the most commonly used antibiotics in the treatment of routine infections, and their use is increasing over time, they can cause a range of hypersensitivity reactions, from mild, delayed-onset cutaneous reactions to life-threatening anaphylaxis in patients with immunoglobulin E (IgE)-mediated allergy.
2-aryloxyketoneAn aryloxyketone with the general formula R2C=O (R=/=H) containing an oxyaryl (-OAr) group bonded to the carbon adjacent to the ketone carbonyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
BRCA1Homo sapiens (human)Potency15.84890.89137.722525.1189AID624202
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency20.59620.00419.984825.9290AID504444
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 8Mus musculus (house mouse)IC50 (µMol)105.00003.02003.02003.0200AID1209730
Insulin-degrading enzymeHomo sapiens (human)IC50 (µMol)7.00000.01402.35207.0000AID1600069
Solute carrier family 15 member 1Homo sapiens (human)Ki28,000.00000.18003.39339.8000AID238858; AID681115
Solute carrier family 15 member 2Homo sapiens (human)Ki4,282.89990.79434.22108.0000AID612540
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki4,300.00003.00006.47788.5000AID681114
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (32)

Processvia Protein(s)Taxonomy
proteolysisInsulin-degrading enzymeHomo sapiens (human)
insulin receptor signaling pathwayInsulin-degrading enzymeHomo sapiens (human)
bradykinin catabolic processInsulin-degrading enzymeHomo sapiens (human)
ubiquitin recyclingInsulin-degrading enzymeHomo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IInsulin-degrading enzymeHomo sapiens (human)
protein catabolic processInsulin-degrading enzymeHomo sapiens (human)
positive regulation of protein bindingInsulin-degrading enzymeHomo sapiens (human)
hormone catabolic processInsulin-degrading enzymeHomo sapiens (human)
peptide catabolic processInsulin-degrading enzymeHomo sapiens (human)
positive regulation of protein catabolic processInsulin-degrading enzymeHomo sapiens (human)
symbiont entry into host cellInsulin-degrading enzymeHomo sapiens (human)
amyloid-beta metabolic processInsulin-degrading enzymeHomo sapiens (human)
proteolysis involved in protein catabolic processInsulin-degrading enzymeHomo sapiens (human)
amyloid-beta clearanceInsulin-degrading enzymeHomo sapiens (human)
amyloid-beta clearance by cellular catabolic processInsulin-degrading enzymeHomo sapiens (human)
insulin metabolic processInsulin-degrading enzymeHomo sapiens (human)
insulin catabolic processInsulin-degrading enzymeHomo sapiens (human)
regulation of aerobic respirationInsulin-degrading enzymeHomo sapiens (human)
monoatomic ion transportSolute carrier family 15 member 1Homo sapiens (human)
protein transportSolute carrier family 15 member 1Homo sapiens (human)
peptide transportSolute carrier family 15 member 1Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 1Homo sapiens (human)
monoatomic ion transportSolute carrier family 15 member 2Homo sapiens (human)
protein transportSolute carrier family 15 member 2Homo sapiens (human)
peptide transportSolute carrier family 15 member 2Homo sapiens (human)
peptidoglycan transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 15 member 2Homo sapiens (human)
dipeptide transportSolute carrier family 15 member 2Homo sapiens (human)
renal absorptionSolute carrier family 15 member 2Homo sapiens (human)
regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwaySolute carrier family 15 member 2Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
antibacterial innate immune responseSolute carrier family 15 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 15 member 2Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
organic anion transmembrane transporter activitySolute carrier family 22 member 8Mus musculus (house mouse)
virus receptor activityInsulin-degrading enzymeHomo sapiens (human)
endopeptidase activityInsulin-degrading enzymeHomo sapiens (human)
metalloendopeptidase activityInsulin-degrading enzymeHomo sapiens (human)
protein bindingInsulin-degrading enzymeHomo sapiens (human)
ATP bindingInsulin-degrading enzymeHomo sapiens (human)
zinc ion bindingInsulin-degrading enzymeHomo sapiens (human)
peptide bindingInsulin-degrading enzymeHomo sapiens (human)
protein homodimerization activityInsulin-degrading enzymeHomo sapiens (human)
insulin bindingInsulin-degrading enzymeHomo sapiens (human)
proton-dependent oligopeptide secondary active transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 1Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 1Homo sapiens (human)
protein bindingSolute carrier family 15 member 2Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 2Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
basolateral plasma membraneSolute carrier family 22 member 8Mus musculus (house mouse)
nucleusInsulin-degrading enzymeHomo sapiens (human)
extracellular spaceInsulin-degrading enzymeHomo sapiens (human)
nucleusInsulin-degrading enzymeHomo sapiens (human)
cytoplasmInsulin-degrading enzymeHomo sapiens (human)
mitochondrionInsulin-degrading enzymeHomo sapiens (human)
peroxisomeInsulin-degrading enzymeHomo sapiens (human)
peroxisomal matrixInsulin-degrading enzymeHomo sapiens (human)
cytosolInsulin-degrading enzymeHomo sapiens (human)
external side of plasma membraneInsulin-degrading enzymeHomo sapiens (human)
cell surfaceInsulin-degrading enzymeHomo sapiens (human)
basolateral plasma membraneInsulin-degrading enzymeHomo sapiens (human)
extracellular exosomeInsulin-degrading enzymeHomo sapiens (human)
peroxisomal matrixInsulin-degrading enzymeHomo sapiens (human)
mitochondrionInsulin-degrading enzymeHomo sapiens (human)
cytosolInsulin-degrading enzymeHomo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
brush borderSolute carrier family 15 member 1Homo sapiens (human)
membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 1Homo sapiens (human)
phagocytic vesicle membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
membraneSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (173)

Assay IDTitleYearJournalArticle
AID573593Antibacterial activity against Fusobacterium necrophorum by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573786Antibacterial activity against Prevotella melaninogenica by by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573802Antibacterial activity against Prevotella melaninogenica assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID574005Antibacterial activity against beta-lactamase producing Clostridium septicum assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573823Antibacterial activity against beta-lactamase producing Clostridium paraputrificum by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID573837Antibacterial activity against beta-lactamase producing Clostridium tertium assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1399278Antimicrobial activity against Escherichia coli isolate SJ 6 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID573784Antibacterial activity against Prevotella bivia by by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573825Antibacterial activity against beta-lactamase producing Clostridium tertium by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID660262Ratio of MIC for wild type Escherichia coli TG1 to MIC for acrB-deficient Escherichia coli KAM3 by two-fold serial dilution method2012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID573783Antibacterial activity against Prevotella buccae by by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID574041Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1399277Antimicrobial activity against Escherichia coli isolate SJ 5 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID1399269Antimicrobial activity against Klebsiella pneumoniae isolate SJ 2 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID660263Ratio of MIC for wild type Salmonella typhimurium SH5014 to MIC for Salmonella typhimurium SH7616 harboring missense mutation in acrA/acrB gene by two-fold serial dilution method2012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID573801Antibacterial activity against Prevotella intermedia assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID574003Antibacterial activity against beta-lactamase producing Clostridium perfringens assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID543419Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID573592Antibacterial activity against Fusobacterium mortiferum by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573591Antibacterial activity against Fusobacterium nucleatum by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID612540Binding affinity to human PepT2 in SKTP cells2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.
AID574023Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID660261Ratio of MIC for wild type Escherichia coli JC7623 to MIC for acrAB-deficient Escherichia coli JZM1202012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID573394Antibacterial activity against Bacteroides fragilis by by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID573397Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron by by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID574006Antibacterial activity against beta-lactamase producing Clostridium tertium assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573599Antibacterial activity against Fusobacterium nucleatum assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573600Antibacterial activity against Fusobacterium mortiferum assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573822Antibacterial activity against beta-lactamase producing Clostridium perfringens by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID574042Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1399266Antimicrobial activity against Proteus mirabilis ATCC 25933 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID573819Antibacterial activity against Veillonella parvula by by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573572Antibacterial activity against beta-lactamase producing Bacteroides uniformis by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573581Antibacterial activity against beta-lactamase producing Bacteroides caccae by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1399276Antimicrobial activity against Escherichia coli isolate SJ 4 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1399263Antimicrobial activity against tolC deficient Escherichia coli JW5503-1 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID573565Antibacterial activity against beta-lactamase producing Bacteroides vulgatus assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1399271Antimicrobial activity against Klebsiella pneumoniae isolate SJ 4 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID573563Antibacterial activity against beta-lactamase producing Bacteroides vulgatus by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID574043Antibacterial activity against beta-lactamase producing Peptoniphilus asaccharolyticus assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID574027Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573824Antibacterial activity against beta-lactamase producing Clostridium septicum by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573800Antibacterial activity against Prevotella bivia assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573551Antibacterial activity against Bacteroides fragilis assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID573573Antibacterial activity against beta-lactamase producing Bacteroides uniformis assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID574033Antibacterial activity against beta-lactamase producing Micromonas micros assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1399272Antimicrobial activity against Klebsiella pneumoniae isolate SJ 5 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID573598Antibacterial activity against Fusobacterium varium assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1399265Antimicrobial activity against Pseudomonas aeruginosa PAO1 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID543411Antimicrobial activity against Shigella sonnei UIH-1 expressing beta-lactamase CTX-M-64 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID573552Antibacterial activity against Bacteroides fragilis assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID681114TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in SKPT cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID1399275Antimicrobial activity against Escherichia coli isolate SJ 3 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1399270Antimicrobial activity against Klebsiella pneumoniae isolate SJ 3 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID573785Antibacterial activity against Prevotella intermedia by by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1219873Inhibition of recombinant human ABCC2 expressed in insect Sf21 cell plasma membrane vesicles assessed as inhibition of transporter-mediated [3H]-estradiol-17beta-glucuronide uptake by liquid scintillation counting analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Oral availability of cefadroxil depends on ABCC3 and ABCC4.
AID574052Antibacterial activity against beta-lactamase producing Finegoldia magna assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573564Antibacterial activity against beta-lactamase producing Bacteroides vulgatus assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1209736Inhibition of human OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID574032Antibacterial activity against beta-lactamase producing Micromonas micros by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID573795Antibacterial activity against Prevotella buccae assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1211549Unbound fraction in Sprague-Dawley rat plasma at 100 uM by equilibrium dialysis method2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID534382Antibacterial activity against Escherichia coli K-12 W1895 transconjugant harboring pCF243 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID573595Antibacterial activity against Fusobacterium nucleatum assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID575417Antimicrobial activity against anrB-deficient Listeria monocytogenes EGD-e at 30 ug after 16 hrs by disk diffusion assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics.
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID574050Antibacterial activity against beta-lactamase producing Finegoldia magna by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1211551Drug uptake in sandwich cultured Sprague-Dawley rat hepatocytes by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1600077Reversible inhibition of human recombinant IDE expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate preincubated for 30 mins followed by 100 fold compound dilution by spectrophotometric analys2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1209730Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake over 20 mins2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1219874Inhibition of recombinant human ABCC3 expressed in baculovirus infected insect Sf21 cell plasma membrane vesicles assessed as inhibition of transporter-mediated [3H]-estradiol-17beta-glucuronide uptake by liquid scintillation counting analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Oral availability of cefadroxil depends on ABCC3 and ABCC4.
AID573590Antibacterial activity against Fusobacterium varium by by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1399274Antimicrobial activity against Escherichia coli isolate SJ 2 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID573601Antibacterial activity against Fusobacterium necrophorum assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID534391Antibacterial activity against Escherichia coli JM109 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID573796Antibacterial activity against Prevotella bivia assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID574026Antibacterial activity against beta-lactamase producing Peptostreptococcus anaerobius assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1600076Inhibition of human recombinant IDE expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate at 0.5 uM preincubated for 10 mins followed by substrate addition and measured after 30 mins by spectro2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID660265Antimicrobial activity against wild type Escherichia coli expressing AcrAB-TolC efflux pump2012European journal of medicinal chemistry, Jun, Volume: 52Computational analysis of structure-based interactions and ligand properties can predict efflux effects on antibiotics.
AID574051Antibacterial activity against beta-lactamase producing Finegoldia magna assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID575340Antimicrobial activity against Listeria monocytogenes EGD-e at 30 ug after 16 hrs by disk diffusion assay2010Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10
The ABC transporter AnrAB contributes to the innate resistance of Listeria monocytogenes to nisin, bacitracin, and various beta-lactam antibiotics.
AID543415Antimicrobial activity against rifampicin-resistant Escherichia coli X1037 transconjugant by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID543423Antimicrobial activity against Escherichia coli XL-1 Blue transconjugant harboring beta-lactamase CTX-M-64 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID534385Antibacterial activity against Escherichia coli K-12 W1895 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID543427Antimicrobial activity against Escherichia coli XL-1 Blue harboring plasmid CL1920 by broth microdilution method2009Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1
Novel chimeric beta-lactamase CTX-M-64, a hybrid of CTX-M-15-like and CTX-M-14 beta-lactamases, found in a Shigella sonnei strain resistant to various oxyimino-cephalosporins, including ceftazidime.
AID534379Antibacterial activity against Citrobacter freundii KHM243 clinical isolate by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID574004Antibacterial activity against beta-lactamase producing Clostridium paraputrificum assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1600069Inhibition of human recombinant IDE expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by spectrophotometri2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1600075Inhibition of human recombinant IDE expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate at 50 uM preincubated for 10 mins followed by substrate addition and measured after 30 mins by spectrop2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID573799Antibacterial activity against Prevotella buccae assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1399279Antimicrobial activity against Escherichia coli ATCC 35218 expressing TEM-1 beta lactamases after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID573597Antibacterial activity against Fusobacterium necrophorum assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1219875Inhibition of recombinant human ABCC4 expressed in baculovirus infected insect Sf21 cell plasma membrane vesicles assessed as inhibition of transporter-mediated [3H]-estradiol-17beta-glucuronide uptake by liquid scintillation counting analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
Oral availability of cefadroxil depends on ABCC3 and ABCC4.
AID534388Antibacterial activity against Escherichia coli JM109 harboring recombinant pKHM-1 by microdilution method2008Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11
KHM-1, a novel plasmid-mediated metallo-beta-lactamase from a Citrobacter freundii clinical isolate.
AID1399268Antimicrobial activity against Klebsiella pneumoniae isolate SJ 1 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID1211550In vivo intrinsic biliary clearance in iv dosed Sprague-Dawley rat by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID238858Binding affinity against membrane transport protein PEPT1 in human Caco-2 cells2005Journal of medicinal chemistry, Jun-30, Volume: 48, Issue:13
Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1.
AID1399260Antimicrobial activity against Acinetobacter baumannii ATCC 19606 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID573834Antibacterial activity against beta-lactamase producing Clostridium perfringens assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573835Antibacterial activity against beta-lactamase producing Clostridium paraputrificum assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID573798Antibacterial activity against Prevotella melaninogenica assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID681115TP_TRANSPORTER: inhibition of Gly-Sar uptake (pH6.0) in Caco-2 cells2005European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, Jan, Volume: 59, Issue:1
Interaction of 31 beta-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1.
AID1600089Inhibition of human recombinant IDE harboring C110L/C171S/C178A/C257V/C414L/C573N/C590S/C789S/C812A/C819A/C904S/C966N/C974A mutant expressed in Escherichia coli BL21 (DE3) cells using ATTO 655- Cys-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Trp as substrate at 30 uM2019European journal of medicinal chemistry, Oct-01, Volume: 179Identification of ebselen as a potent inhibitor of insulin degrading enzyme by a drug repurposing screening.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1399262Antimicrobial activity against Escherichia coli BW25113 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID573836Antibacterial activity against beta-lactamase producing Clostridium septicum assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1399264Antimicrobial activity against Klebsiella pneumoniae ATCC 33495 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID573797Antibacterial activity against Prevotella intermedia assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573594Antibacterial activity against Fusobacterium varium assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1209735Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID1209734Inhibition of mouse OAT1 expressed in CHO cells assessed as inhibition of fluorescein uptake at 500 uM over 20 mins relative to untreated-control2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID573558Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573557Antibacterial activity against beta-lactamase producing Bacteroides thetaiotaomicron assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1211553Drug uptake in iv dosed Sprague-Dawley rat liver after 5 hrs by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID573596Antibacterial activity against Fusobacterium mortiferum assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1211548In vivo apparent biliary clearance in iv dosed Sprague-Dawley rat by LC-MS/MS analysis2012Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 40, Issue:3
In vivo biliary clearance should be predicted by intrinsic biliary clearance in sandwich-cultured hepatocytes.
AID574034Antibacterial activity against beta-lactamase producing Micromonas micros assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1209731Drug uptake by mouse OAT3 expressed in CHO cells at 100 uM after 25 mins by HPLC/UV detection method2013Drug metabolism and disposition: the biological fate of chemicals, Apr, Volume: 41, Issue:4
Organic anion transporter 3 interacts selectively with lipophilic β-lactam antibiotics.
AID573583Antibacterial activity against beta-lactamase producing Bacteroides caccae assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID573582Antibacterial activity against beta-lactamase producing Bacteroides caccae assessed as susceptible isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1399280Antimicrobial activity against Escherichia coli ATCC 25922 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID573574Antibacterial activity against beta-lactamase producing Bacteroides uniformis assessed as resistant isolates by CLSI agar dilution method2008Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9
Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1399273Antimicrobial activity against Escherichia coli isolate SJ 1 after 18 to 20 hrs by microbroth dilution method2018Bioorganic & medicinal chemistry letters, 10-01, Volume: 28, Issue:18
New β-lactam - Tetramic acid hybrids show promising antibacterial activities.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID302010Antileishmanial activity against Leishmania donovani LD-1/MHOM/SD/00-1S in mouse peritoneal macrophages at 80 ug/mL after 48 hrs relative to control2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Structure-activity relationship of antileishmanials neolignan analogues.
AID302008Toxicity against BALB/c mouse macrophages assessed as cell viability2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Structure-activity relationship of antileishmanials neolignan analogues.
AID302011Antileishmanial activity against Leishmania amazonensis MHOM/BR/75-josefa in mouse peritoneal macrophages at 80 ug/mL after 48 hrs relative to control2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Structure-activity relationship of antileishmanials neolignan analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (396)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990205 (51.77)18.7374
1990's84 (21.21)18.2507
2000's37 (9.34)29.6817
2010's48 (12.12)24.3611
2020's22 (5.56)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.15 (24.57)
Research Supply Index6.15 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index73.62 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (46.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials60 (14.78%)5.53%
Trials0 (0.00%)5.53%
Reviews14 (3.45%)6.00%
Reviews0 (0.00%)6.00%
Case Studies43 (10.59%)4.05%
Case Studies0 (0.00%)4.05%
Observational3 (0.74%)0.25%
Observational0 (0.00%)0.25%
Other286 (70.44%)84.16%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Randomized Multicenter Trial of Antibiotic Prophylaxis in Elective Colorectal Surgery: Single-Dose Vs. Three Doses of Second-Generation Cephalosporin [NCT00292708]Phase 3500 participants Interventional2004-05-31Completed
Randomized Controlled Trial of Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery: Oral and Systemic Versus Systemic Antibiotics [NCT00508690]Phase 3584 participants (Actual)Interventional2007-09-30Completed
A Prospective, Randomized Clinical Trial to Treat Intra-abdominal Infection Preventively After Pancreatic Surgery Based on Serum Lactate Changes [NCT05052619]297 participants (Anticipated)Interventional2021-07-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]